These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 30990265)

  • 21. Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.
    Kruse G; Wong BJ; Duh MS; Lefebvre P; Lafeuille MH; Fastenau JM
    Pharmacoeconomics; 2015 Oct; 33(10):1049-67. PubMed ID: 25963579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of patient and public participation in health technology assessment and coverage decisions.
    Menon D; Stafinski T
    Expert Rev Pharmacoecon Outcomes Res; 2011 Feb; 11(1):75-89. PubMed ID: 21351860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health.
    Ghabri S; Hamers FF; Josselin JM
    Pharmacoeconomics; 2016 Jun; 34(6):617-24. PubMed ID: 26829942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of health technology assessment bodies in shaping drug development.
    Ciani O; Jommi C
    Drug Des Devel Ther; 2014; 8():2273-81. PubMed ID: 25419117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
    Kaltenthaler E; Boland A; Carroll C; Dickson R; Fitzgerald P; Papaioannou D
    Health Technol Assess; 2011 May; 15(22):1-82, iii-iv. PubMed ID: 21561569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. WHY PATIENTS SHOULD BE INVOLVED IN HEALTH TECHNOLOGY ASSESSMENT.
    Wale J; Scott AM; Hofmann B; Garner S; Low E; Sansom L
    Int J Technol Assess Health Care; 2017 Jan; 33(1):1-4. PubMed ID: 28528585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient Involvement in the Health Technology Assessment Process in Taiwan.
    Chen KA; Huang LY; Gau CS
    Front Med Technol; 2021; 3():732160. PubMed ID: 35128522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The project data sphere initiative: accelerating cancer research by sharing data.
    Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
    Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Update of the Mexican Health Care Formulary and Supply Catalog in the Context of the Health Technology Assessment.
    Ríos PR; Rivera AG; Oropeza IR; Ramírez OC
    Value Health Reg Issues; 2014 Dec; 5():29-34. PubMed ID: 29702784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Standardized reporting for rapid relative effectiveness assessments of pharmaceuticals.
    Kleijnen S; Pasternack I; Van de Casteele M; Rossi B; Cangini A; Di Bidino R; Jelenc M; Abrishami P; Autti-Rämö I; Seyfried H; Wildbacher I; Goettsch WG
    Int J Technol Assess Health Care; 2014 Nov; 30(5):488-96. PubMed ID: 25747557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. STAKEHOLDER INVOLVEMENT IN HEALTH TECHNOLOGY ASSESSMENT AT NATIONAL LEVEL: A STUDY FROM IRAN.
    Yazdizadeh B; Shahmoradi S; Majdzadeh R; Doaee S; Bazyar M; Souresrafil A; Olyaeemanesh A
    Int J Technol Assess Health Care; 2016 Jan; 32(3):181-9. PubMed ID: 27524462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FRAMEWORK FOR USER INVOLVEMENT IN HEALTH TECHNOLOGY ASSESSMENT AT THE LOCAL LEVEL: VIEWS OF HEALTH MANAGERS, USER REPRESENTATIVES, AND CLINICIANS.
    Gagnon MP; Desmartis M; Gagnon J; St-Pierre M; Rhainds M; Coulombe M; Tantchou MD; Légaré F
    Int J Technol Assess Health Care; 2015 Jan; 31(1-2):68-77. PubMed ID: 25952585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenges to decision-making processes in the national HTA agency in Brazil: operational procedures, evidence use and recommendations.
    Yuba TY; Novaes HMD; de Soárez PC
    Health Res Policy Syst; 2018 May; 16(1):40. PubMed ID: 29751764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient perspective in health technology assessment of pharmaceuticals in Finland.
    Kleme J; Pohjanoksa-Mäntylä M; Airaksinen M; Enlund H; Kastarinen H; Peura P; Hämeen-Anttila K
    Int J Technol Assess Health Care; 2014 Jul; 30(3):306-11. PubMed ID: 25136762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Community views and perspectives on public engagement in health technology assessment decision making.
    Wortley S; Tong A; Howard K
    Aust Health Rev; 2017 Mar; 41(1):68-74. PubMed ID: 27050156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health technology assessment: an Australian perspective.
    Hailey DM; Crowe BL
    Med Prog Technol; 1991; 17(2):103-9. PubMed ID: 1835749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Practical tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European Network for Health Technology Assessment, EUnetHTA.
    Kristensen FB; Lampe K; Chase DL; Lee-Robin SH; Wild C; Moharra M; Garrido MV; Nielsen CP; Røttingen JA; Neikter SA; Bistrup ML;
    Int J Technol Assess Health Care; 2009 Dec; 25 Suppl 2():1-8. PubMed ID: 20030885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Jordan Food and Drug Administration: Comparison of its Registration Process with Australia, Canada, Saudi Arabia and Singapore.
    Haqaish WSA; Obeidat H; Patel P; Walker S
    Pharmaceut Med; 2017; 31(1):21-30. PubMed ID: 28572733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [HERA-QUEST: HTA evaluation of generic pharmaceutical products to improve quality, economic efficiency, patient safety and transparency in drug product changes in hospitals].
    Gyalrong-Steur M; Kellermann A; Bernard R; Berndt G; Bindemann M; Nusser-Rothermundt E; Amann S; Brakebusch M; Brüggmann J; Tydecks E; Müller M; Dörje F; Kochs E; Riedel R
    Z Evid Fortbild Qual Gesundhwes; 2017 Apr; 121():5-13. PubMed ID: 28545614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.